HealthInvest Partners AB Purchases Shares of 39,573 Janux Therapeutics, Inc. (NASDAQ:JANX)

HealthInvest Partners AB acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 39,573 shares of the company’s stock, valued at approximately $2,078,000. Janux Therapeutics makes up 1.0% of HealthInvest Partners AB’s holdings, making the stock its 26th largest position. HealthInvest Partners AB owned about 0.08% of Janux Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Plato Investment Management Ltd grew its position in Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after acquiring an additional 187 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares in the last quarter. Avanza Fonder AB bought a new stake in shares of Janux Therapeutics during the fourth quarter worth $139,000. Chicago Capital LLC acquired a new stake in shares of Janux Therapeutics in the fourth quarter valued at $230,000. Finally, Chicago Partners Investment Group LLC bought a new position in shares of Janux Therapeutics in the third quarter valued at about $239,000. Institutional investors and hedge funds own 75.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Scotiabank lifted their target price on Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a research note on Wednesday, December 4th. Stifel Nicolaus upped their price target on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Leerink Partners lifted their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 3rd. Finally, Leerink Partnrs raised Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $89.90.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $36.01 on Monday. Janux Therapeutics, Inc. has a 52-week low of $13.20 and a 52-week high of $71.71. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of -30.78 and a beta of 3.16. The firm’s 50-day moving average is $46.27 and its 200-day moving average is $48.10.

Insider Transactions at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the sale, the insider now owns 82,139 shares in the company, valued at approximately $3,473,658.31. This trade represents a 3.90 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO David Alan Campbell sold 15,000 shares of Janux Therapeutics stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $67.00, for a total transaction of $1,005,000.00. Following the sale, the chief executive officer now directly owns 242,054 shares of the company’s stock, valued at $16,217,618. The trade was a 5.84 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 61,668 shares of company stock worth $3,582,515. 29.40% of the stock is owned by company insiders.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.